Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Any methods that may improve confirmation or early detection of progression are highly desirable. T2 relaxometry shows great promise in the monitoring of GBM patients following complex therapy. We found WB metrics, such as median 1/T2, correlated with PFS and were able to distinguish progression from pseudo-progression. A deep neural network trained on automatically segmented 1/T2 data achieved an F1 accuracy of 85% in classifying progression with a threshold of 18 months.